|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.26 CHF | -1.12% |
|
+0.37% | +4.25% |
| 10:39pm | Global drugmakers rush to boost US presence as tariff threat looms | RE |
| 05:24pm | Novartis Seen Largely Shielded From US Tariffs | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Innovative Medicines | 4.08TCr | 4.4TCr | 4.34TCr | 4.67TCr | 5.17TCr | |||||
Total Assets | 8.31TCr | 7.92TCr | 7.55TCr | 9.99TCr | 10TCr | |||||
Interest Expense | - | - | - | -86Cr | -100.6Cr | |||||
Income Tax Expense | - | - | - | 55Cr | 170.1Cr | |||||
CAPEX | -242.5Cr | -270.4Cr | -263.3Cr | -106Cr | -136.6Cr | |||||
EBT | - | - | - | 912.3Cr | 1.36TCr | |||||
Gross Profit | 2.99TCr | 3.22TCr | 3.18TCr | 3.42TCr | 3.89TCr | |||||
D&A | 426.5Cr | 476.2Cr | 481.7Cr | 513.5Cr | 459.9Cr | |||||
Operating Income | 917.2Cr | 1.07TCr | 878.6Cr | 976.9Cr | 1.45TCr | |||||
Net Income | - | - | - | 1.48TCr | 1.19TCr | |||||
Sandoz | 988.8Cr | 987.2Cr | 948.2Cr | - | - | |||||
Total Assets | 1.68TCr | 1.62TCr | 1.61TCr | - | - | |||||
CAPEX | -40Cr | -48Cr | -46Cr | - | - | |||||
Gross Profit | 463.6Cr | 472.5Cr | 450.4Cr | - | - | |||||
D&A | 69Cr | 49Cr | 46Cr | - | - | |||||
Operating Income | 104.3Cr | 160Cr | 144.8Cr | - | - | |||||
Optical Healthcare | ||||||||||
Alcon | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Corporate (Including Eliminations) | -81Cr | -96Cr | -102.4Cr | - | - | |||||
Total Assets | 3.21TCr | 3.64TCr | 2.59TCr | - | - | |||||
CAPEX | -21Cr | -31Cr | -22Cr | - | - | |||||
Gross Profit | 24Cr | 6.7Cr | 3.7Cr | - | - | |||||
D&A | 15Cr | 18Cr | 17Cr | - | - | |||||
Operating Income | -6.3Cr | -60Cr | -103.7Cr | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 1.65TCr | 1.68TCr | 1.77TCr | 1.8TCr | 2.11TCr | |||||
Total Assets | 3.99TCr | 3.71TCr | 3.54TCr | 3.41TCr | 3.5TCr | |||||
Other | 1.9TCr | 2.08TCr | 2.01TCr | 1.59TCr | 1.85TCr | |||||
Total Assets | 783.7Cr | 735.1Cr | 824.1Cr | 426.9Cr | 460.3Cr | |||||
China | 257.3Cr | 305.2Cr | 312.8Cr | 326.7Cr | 389Cr | |||||
Total Assets | 71Cr | 70Cr | 60Cr | 55Cr | 53Cr | |||||
Germany | 451.8Cr | 487Cr | 427.8Cr | 336.7Cr | 366Cr | |||||
Total Assets | 260.7Cr | 237.8Cr | 222.9Cr | 8.8Cr | 155.4Cr | |||||
France | 244.2Cr | 252.2Cr | 225.7Cr | 174.9Cr | 179.2Cr | |||||
Total Assets | 411.5Cr | 361.5Cr | 318.8Cr | 308.5Cr | 264Cr | |||||
Switzerland | 80Cr | 87Cr | 97Cr | 130.8Cr | 131.5Cr | |||||
Total Assets | 3.49TCr | 2.58TCr | 2.37TCr | 1.94TCr | 1.88TCr | |||||
United Kingdom | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Japan | 280.4Cr | 268.3Cr | 220.5Cr | 192.4Cr | - | |||||
Total Assets | 31Cr | 22Cr | 16Cr | 12Cr | - |
- Stock Market
- Equities
- NOVN Stock
- Financials Novartis AG
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition